Dopamine (DA) is considered crucial for the rewarding effects of drugs of abuse, but its role in addiction remains unclear. Positron emission tomography (PET) is the fi rst technology used for in vivo measurement of components of the dopaminergic system in the human brain. In this article, we review the major fi ndings from PET imaging studies on the involvement of DA in drug addiction, including presynaptic DA synthesis, vesicular monoamine transporter 2, the DA transporter, and postsynaptic DA receptors. These results have corroborated the role of DA in addiction and increased the understanding of its underlying mechanisms.
Brain Dopaminergic System
Dopamine (DA) is a catecholamine neurotransmitter in the nervous system. It has many functions in the brain, including punishment, reward, voluntary movement, mood, attention, motivation, sleep, working memory, and learning [1] . DA is synthesized by the hydroxylation and decarboxylation of L-tyrosine in DA neurons and, before being released into the synapse in response to an action potential, it is stored within presynaptic vesicles (Fig. 1) . The action of DA occurs by binding to postsynaptic DA receptors, resulting in the formation of second messengers. There are fi ve subtypes of DA receptors, which can be grouped into two classes or families: D1-like and D-2 like [1, 2] . The D1-like receptor family comprises the D1 and D5 receptors, encoded by genes with no introns, acting by way of Gs-proteins and activating adenylyl cyclase, thus increasing cAMP production [3, 4] .
The D2-like receptor family comprises the D2, D3, and D4 receptors, encoded by genes containing introns. D2-like receptors act via Gi-proteins, inhibit adenylyl cyclase activity, and thus decrease cAMP activity [3, 5] .
The action of DA in the synapse is terminated primarily by reuptake to the presynaptic membrane through the dopamine transporter (DAT) [6] . Otherwise, DA is partially removed by oxidation by monoamine oxidase orcatechol-O-methyltransferase in the synaptic cleft ( Fig. 1 ).
T h e d o p a m i n e r g i c n e u r o n s , w h o s e p r i m a r y neurotransmitter is DA, interconnect many areas of the brain to form a system which originates in the substantia nigra (SN) pars compacta, ventral tegmental area (VTA), and hypothalamus. The dopaminergic system is typically divided into four major pathways: mesocortical (from the VTA to the frontal cortex), mesolimbic (from the VTA to the nucleus accumbens), nigrostriatal (from the SN to the striatum), and tuberoinfundibular (from the hypothalamus to the pituitary gland). The mesostriatal and mesocortical pathways are currently recognized to contribute most to drug addiction [7] .
Drug Addiction
The term addiction is derived from the Latin verb addicere, which referred to the Roman court action of binding a person to another. From the 17th century, addiction has been used to refer to psychoactive substances (e.g. alcohol, tobacco, heroin) which cross the blood-brain barrier, temporarily altering the chemical milieu of the brain [8] .
Currently, addiction is identified as continued involvement with a drug, despite the negative consequences associated with it -such as compulsive drug seeking and taking, loss of control over drug-taking, or emergence of a negative emotional state (e.g., dysphoria, anxiety, irritability) -when access to the drug is prevented or terminated [9] .
Recently, "behavioral addiction" has also been proposed, but is beyond this review and has been described in detail elsewhere [10] [11] [12] [13] [14] [15] [16] [17] [18] .
The neuronal basis of addiction has been guided by the premise that the motivation of an addict to take drugs results from the desire to experience the hedonic (i.e., rewarding) effects or from the desire to avoid the anhedonia and aversive consequences of withdrawal [19] . There are mounting studies suggesting that the rewarding properties of addictive drugs depend on their ability to provoke DA release in the brain [20] [21] [22] .
Over the past few decades, the progressive development of functional neuroimaging technology, especially positron emission tomography (PET), has made possible the elucidation of brain functions associated with addiction [23] [24] [25] .
PET Imaging of Alterations of the Brain Dopaminergic System in Drug Addiction
PET is a technique that measures the radioactivity released by specific radioligands, and can therefore be used to generate cross-sectional brain images with anatomical or detailed functional information about changes in neurotransmitter responsiveness or receptor expression [26] .
The commonly-used isotopes 11 C, 13 N, 15 O, and 18 F have short half-lives, making possible repeated studies within a short time-span. Moreover, the quantity of PET tracers injected is too low (in the nanomolar range) to cause harm.
The dopaminergic system has been identified as a key substrate for the rewarding effects of abused drugs and PET was the first technology that enabled the direct measurement of components of the DA system in the living human brain [27] . PET imaging studies have also shown that in drug-addicted individuals, DA function is markedly disrupted [25, 28] . In this article, we review PET radiotracers that are currently available for imaging the dopaminergic system in drug addiction and the main findings of in vivo imaging studies.
PET Studies of Presynaptic DA Synthesis
Addictive drugs exhibit a wide range of structures and actions, but the unifying principle appears to be that they each acutely enhance DA neurotransmission by means that dissociate it from normal drive by environmental cues [29, 30] . [32, 33] . Studies with PET and radionuclidelabeled L-dopa and their main fi ndings are summarized in Table 1 .
In cocaine addiction, PET imaging with
terminal activity in the striatum of detoxified cocaine abusers compared with controls [34, 35] . Also, a decrease in presynaptic DA activity during cocaine abstinence or withdrawal is associated with relapse [36, 37] .
Methamphetamine (MA), another prevalent psychostimulant drug of abuse, induces more deleterious changes in the brain than cocaine when a toxic dose is used [35] .
This is evident from the significant reductions in striatal in MA abuse [35] .
In alcohol addiction, although there is no difference in the net influx of striatal [ 18 F] dopa (an index of DA synthesis) between detoxifi ed alcoholic patients and control subjects [33] , fi ndings from several studies have shown that low DA synthesis correlates with alcohol craving, negative mood states, and a high risk of relapse [33, 38] . This study suggests that the magnitude of the change in presynaptic DA function correlates with the patients' degree of inability to modify their behavior [39] .
In smokers, significantly higher [ 18 F] dopa uptake occurs in the putamen and caudate than in non-smokers, which suggests that smoking is related to greater DA activity in the human basal ganglia, and nicotine-induced DA activity may be a mechanism relevant to dependence on cigarette smoking [40] .
Ecstasy (+/-3,4-methylenedioxymethamphetamine, MDMA) is a popular recreational drug with known neurotoxicity. Its potential long-term effects on dopaminergic function have been verified recently by an in vivo PET study in human subjects. In the study by Tai et al. [41] [ 18 F] dopa uptake in the putamen was 9% higher in exusers of ecstasy than in controls, even after >3 years of abstinence.
PET Studies of Vesicular Monoamine Transporter 2
Vesicular monoamine transporter 2 (VMAT2) is a protein responsible for transporting monoamine neurotransmitters from the cytoplasm into synaptic vesicles [42] , so it plays an important role in regulating the presynaptic DA concentration. The most-used ligand in VMAT2-binding studies in vivo is 11 C-labeled dihydrotetrabenazine (DTBZ).
Binding of [ 11 C] DTBZ to VMAT2 is commonly considered
to be a stable marker of DA neuronal integrity and an in vivo marker of DA nerve terminals [43] . PET imaging studies of VMAT2 in drug addiction and the main findings are summarized in Table 2 . Postmortem studies comparing the VMAT2 density in cocaine abusers with healthy subjects using radiolabeled DTBZ found signifi cantly reduced [ 3 H] DTBZ binding in the striatum of cocaine abusers [44] . A recent in vivo PET study with [ 11 C] DTBZ confirmed the previous in vitro findings, suggesting compensatory down-regulation of the DA storage vesicles in response to chronic cocaine abuse and/ or a loss of dopaminergic terminals [45] .
Animal studies and preclinical investigations have established that drugs of abuse produce long-term changes in DA neuronal integrity. In a PET imaging investigation of "heavy" MA users, the striatal [ 11 C] DTBZ binding was decreased by 10%, even after at least 3 months of abstinence, reflecting the long-lasting effect of MA on VMAT2 [46] . And in the study of Boileau et al. [43] , who used human subjects to measure striatal days; range, 1-90 days) was increased [47] . One potential explanation for this increase is that [ 11 C] DTBZ binding not only reflects DA synaptic integrity, but also indicates changes in the endogenous vesicular DA storage levels with unchanged VMAT2 protein expression [47] . This hypothesis was verifi ed by Kilbourn et al. [48] , who conducted a systematic study in rats, in which in vivo PET analysis of [ 11 C] DTBZ binding was examined as a function of DA by AMPH not to changes in presynaptic VMAT2 but an insufficient drug dose to significantly deplete striatal DA [43] . Therefore, more systematic preclinical studies are required to optimally guide the extraction of clinically useful information from [
11 C] DTBZ PET imaging of the human brain [49] .
PET Studies of the Dopamine Transporter
The DAT is a membrane-spanning protein that pumps DA from the extracellular space into the presynaptic neuronal cytosol, from which other transporters sequester DA into vesicles for storage and later release (Fig. 1) . DA reuptake via the DAT is the primary mechanism by which DA is cleared from synapses and DATs have been used as markers of presynaptic DA terminals [50] . The DAT is also a target for addictive drugs such as cocaine and AMPH. [51] (Table 3) .
Cocaine was initially labeled with 11 C to track the distribution and pharmacokinetics of this powerful stimulant and drug of abuse in the human brain and body. It was soon discovered that [ 11 C] cocaine is also a sensitive radiotracer for DAT availability [52] . Because the major molecular target of cocaine is the DAT, the question of whether chronic cocaine use alters the DAT has been investigated [53] . Although postmortem studies have shown decreased DAT in cocaine addicts [54] , one PET study using [ 11 C] cocaine reported no significant differences in DAT binding between cocaine-dependent individuals who had withdrawn for >5 days and controls [53] .
Besides cocaine per se, some of its congeners have also been labeled with positron-releasing radionuclides to study the function of the DAT in drug addiction in vivo.
2β-carboxymethoxy-3β-(4-iodophenyl) tropane (β-CIT),
one of these congeners, has been labeled with 11 C for PET studies. In an autoradiographic study on human brain sections and a PET study of monkeys and humans, [ 11 C] β-CIT was found to accumulate markedly in the striatum where DATs are mostly located [55] . In an in vivo PET study with [ 11 C] β-CIT, decreased DAT has been found in the putamen in early Parkinson's disease [56] , but so far it has not been used in the study of drug abuse. indicating that it is a suitable tracer for studying the DAT in vivo with PET [57] . In the PET study with [ 18 F] FCT in the cocaine self-administration model with monkeys, the laterality of DAT function was changed even before enough cocaine was consumed to produce significant overall changes in receptor and transporter availability [58] . [60, 61] . A PET imaging study with [ 11 C] WIN 35,428 demonstrated that heroin users have a signifi cantly lower DAT uptake than healthy controls [62] . [ has also revealed a reduction of the DAT in MA abusers and in baboons after MA injection [63] [64] [65] [66] .
Methylphenidate (MP, Ritalin), a psychostimulant, d-threo-MP to the DAT, suggesting that it is a useful PET tracer for imaging presynaptic dopaminergic neurons [67] . A PET imaging study using pretreatment with MP showed a marked decrease of [ 11 C] d-threo-MP binding in the human brain [68] . However, PET imaging did not find a significant
alcoholics and non-alcoholics, which means that prolonged alcohol abuse might have no significant impact on DAT availability [69] . 
PET Studies of Postsynaptic DA Receptors
The radiolabeled ligands for PET imaging of DA receptors in drug addiction and the main fi ndings are listed in Table 4 .
Spiroperidol (spiperone) is a potent D2 receptor antagonist [70] . In 1984, in vivo studies in rats and primates showed that 18 F-labeled spiroperidol has high specific activity for D2 receptors [71] . Latterly, N-methylspiroperidol (NMSP), the amide N-methyl analog, has also been radiolabeled with 18 F. In vivo PET imaging in the baboon brain showed that striatal uptake and retention is five- [72] . In PET studies with receptor availability than normal controls, especially during early detoxifi cation [53, 73] , and this may be present even 3-4 months after detoxifi cation [74] . D2 receptor availability was also found to be associated with decreased metabolism in several regions of the frontal lobe, most markedly the orbito-frontal cortex and cingulate gyri [73] . In vivo PET imaging in baboons showed that AMPH pretreatment induces decreases in [ 18 F] NMSP in the corpus striatum,
suggesting that PET imaging with [ 18 F] NMSP can also be used to monitor drug-induced elevations in endogenous DA levels [75] .
Raclopride is a synthetic compound that acts as an antagonist on D2 receptors and 11 C-labeled raclopride is the most commonly-used tracer in the PET imaging of addiction to cocaine [76] , alcohol [69, 77, 78] , MA [79] , and heroin [80] .
In cocaine abusers with intravenous administration of 48 mg cocaine (a typical "street" dose), [ 11 C] raclopride occupancy at D2 receptors was decreased significantly, suggesting that higher DA concentrations compete at the receptor site [76] . Alcoholics showed lower D2 receptor levels in the caudate and putamen during early detoxifi cation and in the caudate during late detoxification, which is in line with the idea that D2 mechanisms are involved in alcohol dependence [69, 77, 78] . Heroin-dependent individuals [80] and MA abusers [79] both showed signifi cantly lower D2 receptor availability than comparison subjects. labeled benzamide derivative that binds reversibly to D2 receptors [81] . In PET imaging with [ 18 F] FCP, Nader and colleagues [82] found that the baseline D2 receptor availability is negatively correlated with the rate of cocaine self-administration. fallypride PET imaging study, nicotine-dependent smokers displayed signifi cantly less availability of D2/D3 receptors within the bilateral putamen, functionally covering parts of the dorsal striatum, compared to never-smoking subjects [83] . [33] .
For the D1 receptor, [ receptors in humans [84] , and its D1 receptor selectivity has recently been re-evaluated [85] . With PET and the radiotracer [ 11 C] NNC 112, Martinez et al. [86] found no difference between cocaine abusers and normal controls. However, studies of striatal D1 receptors [87] . A significant reduction in [ 11 C] SCH23390 binding potential has been found in the striatum of smokers compared to nonsmokers, most prominently in the ventral striatum, suggesting a reduction in D1 receptor density in the ventral striatum of cigarette smokers [88, 89] . DA can be divided into those that interfere with the acute effects of a drug and those that compensate for the chronic effects of long-term use linked to its dopaminergic effects [90] .
Conclusions
In the future, the role of PET may become more important in drug-addiction diagnosis and guiding therapy. Enhancements in image resolution and specific molecular tags will permit accurate diagnoses, based on both structural and molecular changes in the brain. However, the use of PET to study the role of the dopaminergic system in drug addiction is still in its infancy.
Although available PET studies have mainly focused on DA, its interactions with other neurotransmitters such as GABA, glutamate, and serotonin also play important roles in modulating the magnitude of DA responses to drugs.
Currently, several imaging modalities complement each other, and image fusion has become common in diagnostics and treatment [91] . In recent years, the multimodality imaging technologies such as PET/CT and PET/MRI have shown promising results, indicating great potential for clinical and preclinical uses [92] . There is no doubt that future PET research on drug addiction will benefi t greatly from multimodal imaging approaches. Furthermore, the development of new PET tracers that are sensitive to the targets of DA and other neurotransmitter systems, along with the findings of multimodal imaging studies that are integrated into genetic and neurobiological research, will increase our understanding of the mechanisms underlying drug addiction.
